CA209-9KY: Phase II Study of IMRT Re-Irradiation and Concurrent/Adjuvant Nivolumab (Nivo) in Patients With Loco Regionally Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC) ― Toxicity and Quality of Life (QoL) Results
Year: 2021
Type: article
Study design: Clinical Trial
Authors: N.F. Saba, S. Wong, W.A. Stokes, M. Rupji, Y. Liu, S. Rudra, J.E. Bates, C. Steuer, J.S. Remick, K. Cummings, N.P. Joshi, N.M. Woody, J.L. Geiger, M.R. Patel, N.C. Schmitt, M.W. El-Deiry, G. Chen, A. Wieland, M. Abazeed, D.J. Adelstein, R. Ahmed, K.A. Higgins, J.J. Beitler, D.M. Shin, W.J. Curran, M.W. McDonald, S. Koyfman
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3208788824